AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta)... Show more
AbbVie Inc. (ABBV) has traded with a modestly positive bias over the trailing month, with shares rising from the low-$270s in early October to roughly $291 in recent sessions. The advance has been driven primarily by a strong third-quarter earnings report and an accompanying lift in full-year guidance, rather than by a single outsized catalyst. Broader sentiment toward large-cap pharmaceuticals has remained constructive, and AbbVie's combination of double-digit revenue growth in key franchises plus a growing dividend has kept the stock in focus for both growth- and income-oriented investors.
AbbVie is a global, research-based biopharmaceutical company that discovers, develops, and commercializes innovative therapies across four core areas: immunology, oncology, neuroscience, and aesthetics. Its flagship growth drivers are Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat a range of inflammatory and autoimmune conditions, including psoriasis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis. The company also markets Botox and Juvederm in aesthetics, Vraylar and migraine treatments Ubrelvy and Qulipta in neuroscience, and Venclexta and Imbruvica in oncology.
AbbVie has spent recent years navigating the loss of exclusivity on Humira, once the world's best-selling drug, by building a diversified portfolio of newer medicines with long patent protection. Its competitive strengths include deep commercial scale across immunology, an expanding pipeline, and strong free-cash-flow generation that supports both dividend growth and targeted acquisitions.
AbbVie's third-quarter 2026 results, reported in late October, anchored the stock's recent performance. Total revenue increased about 10% to $17.4 billion, beating management's expectations, while adjusted EPS of $3.82 came in $0.07 above the guidance midpoint. Immunology led the way, with revenue approaching $9.2 billion on 16.6% operational growth. Skyrizi generated nearly $5.8 billion in sales, up 22.9% operationally, and Rinvoq grew 24.3% to $2.7 billion, more than compensating for Humira's 30.6% decline.
Management raised full-year revenue guidance by $200 million to approximately $67.8 billion and lifted adjusted EPS guidance to $13.95–$13.99, marking the third revenue increase of the year. The company also raised its quarterly dividend by 5.2% to $1.82 per share. Other developments included U.S. FDA approval of Skyrizi subcutaneous induction for Crohn's disease, the FDA approval of Juvmo for Parkinson's disease, and the completion of the Apogee Therapeutics acquisition, which adds the atopic dermatitis candidate zumilokibart to the pipeline.
Tickeron's Trending AI Robots page is a curated showcase of the platform's top-performing and most relevant AI trading bots. While Tickeron offers hundreds of AI-driven trading bots that collectively trade thousands of tickers, only the strongest and most relevant strategies surface in this section. The bots vary widely in approach, trading timeframe, and performance metrics, ranging from short-term momentum models to longer-horizon trend-following systems. This diversity lets traders and investors browse strategies that align with their own risk tolerance and objectives. Exploring the Trending AI Robots page offers a way to observe how automated systems are positioned across the market.
Looking ahead, the central question for AbbVie is whether Skyrizi and Rinvoq can sustain their momentum through 2026 and into the next decade as competition in immunology intensifies. Investors will watch new indication launches, including Rinvoq's anticipated U.S. approvals for vitiligo and alopecia areata, and the ramp of Skyrizi's subcutaneous induction in Crohn's disease. In neuroscience, the early commercialization of Juvmo and continued growth from Vraylar and the oral CGRP migraine franchise will be key monitors.
Macro and policy risks remain relevant, including U.S. drug-pricing reform under the Inflation Reduction Act and payer reimbursement dynamics. The aesthetics segment, which has lagged amid softer consumer demand, and the oncology portfolio, pressured by Imbruvica's decline, will also be watched for signs of stabilization. AbbVie's strong free cash flow and pipeline progression provide visibility, but clinical trial outcomes and regulatory decisions carry inherent uncertainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ABBV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 03, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 27 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 57%.
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 18 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABBV as a result. In 36 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +0.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 222 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
ABBV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 217 of 349 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.421). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.700). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a research-based pharmaceutical company
Industry PharmaceuticalsMajor